Ionis Pharmaceuticals
IONS | NASDAQ
$28.01
-$1.05 (-3.61%)
At close: Nov 16, 2026, 4:00 PM ET
$28.06
+$0.05 (+0.18%)
After-hours:
Nov 16, 2026, 7:41 PM ET
Ionis Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Key Executives
| Name | Position |
|---|---|
| Brett Monia | Founder, Chief Executive Officer & Director |
| Elizabeth L. Hougen | Executive Vice President of Finance & Chief Financial Officer |
| Patrick R. O'Neil | Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary |
| Brian Birchler | Executive Vice President of Corporate & Development Operations |
| C. Frank Bennett | Executive Vice President & Chief Scientific Officer |
| D. Wade Walke | Senior Vice President of Investor Relations |
| Darren Gonzales | Chief Accounting Officer & Senior Vice President |
| Eric E. Swayze | Executive Vice President & Head of Research |
| Eugene Schneider | Executive Vice President, Chief Clinical Development & Operations Officer |
| Richard S. Geary | Strategic Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 4 | Filing |
| Oct 19, 2026 | 4 | Filing |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
Ionis Pharmaceuticals
| Country | United States |
| IPO Date | May 17, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,480 |
| CEO | Brett Monia |
Contact Details
2855 Gazelle Court Carlsbad,
California 92010 United States
Stock Details
| Ticker Symbol | IONS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000874015 |
| CUSIP Number | 462222100 |
| ISIN Number | US4622221004 |
| SIC Code | 2834 |
Recent News
- 13 hours ago / marketbeat.comIonis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
- 18 hours ago / seekingalpha.comIonis Pharmaceuticals, Inc. (IONS) Presents at UBS Global Biopharma Conference 2026 Transcript
- 4 days ago / globenewswire.comWolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors
- 5 days ago / zacks.comHere's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings
- 6 days ago / businesswire.comIonis to present at upcoming investor conferences
- 7 days ago / fool.comIonis: 3 Key Takeaways for Long-Term Investors
- 7 days ago / seekingalpha.comIonis Pharmaceuticals: Q3 Triggers The Latest Selloff On Tryngolza Disappointment
- 7 days ago / seekingalpha.comIonis Pharmaceuticals, Inc. (IONS) Q3 2026 Earnings Call Transcript
- 8 days ago / benzinga.comWhy Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?
- 8 days ago / marketbeat.comWhat Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call
Add to Watchlist
Select watchlists to add or remove IONS